Actively Recruiting
Comparing PD-1 and PD-L1 Immune Checkpoint Inhibitors With Chemotherapy, With or Without Bevacizumab, for Women Aged 18 to 75 With Metastatic, Persistent, or Recurrent Cervical Cancer
Led by N.N. Alexandrov National Cancer Centre · Updated on 2026-05-28
120
Participants Needed
1
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of PD-1 and PD-L1 immune checkpoint inhibitors combined with chemotherapy, with or without bevacizumab, in patients with metastatic, persistent, or recurrent cervical cancer. This randomized study aims to compare these treatment approaches to better understand their impact on survival and disease control in this patient population. The trial is sponsored by N.N. Alexandrov National Cancer Centre and includes patients aged 18 to 75 years with confirmed cervical cancer meeting specific clinical stages and conditions. Participants will be assigned to one of three groups PD-1 inhibitor plus chemotherapy, PD-L1 inhibitor plus chemotherapy, or chemotherapy with or without bevacizumab. Each group receives six courses of chemotherapy every 21 days, with drugs including cisplatin or carboplatin and paclitaxel. Bevacizumab may be added based on the group. If patients show a complete or partial response or disease stabilization, maintenance therapy continues with the assigned immune checkpoint inhibitor or bevacizumab until disease progression or unacceptable side effects occur. During the study, participants will be monitored for overall survival, median overall survival, objective response rate, duration of response, and disease-free survival over periods ranging from two to five years. Assessments include treatment response and disease progression. Safety and tolerability will be followed throughout. The study involves regular visits for treatment administration and evaluations, with an average follow-up of up to 36 months for primary outcomes and up to 60 months for secondary outcomes.
CONDITIONS
Brief Title
PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer
Research Team
Y
Yana Kamko
S
Sergey Mavrichev
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here